On and effective June 15, 2022, VistaGen Therapeutics, Inc. (the Company) terminated the employment of H. Ralph Snodgrass, Ph.D., who served as the Company's President and Chief Scientific Officer.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
3.9 USD | -0.76% | -1.52% | -24.12% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-24.12% | 105M | |
+18.72% | 125B | |
+14.53% | 109B | |
-2.88% | 24.74B | |
+4.63% | 22.67B | |
-9.58% | 18.14B | |
-41.04% | 16.67B | |
-11.83% | 16.64B | |
+1.46% | 13.45B | |
+24.22% | 11.32B |
- Stock Market
- Equities
- VTGN Stock
- News Vistagen Therapeutics, Inc.
- VistaGen Therapeutics, Inc. Terminates Employment of H. Ralph Snodgrass as President and Chief Scientific Officer